Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 7/20 | 0.39 |
| ▸ | GSK3B | P49841 | 4/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 5/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25257863 | 1.00 | DYRK1A (0.39) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| Hydrochloric Acid SCHEMBL30439503 | 0.99 | DYRK1A (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| SCHEMBL30438490 | 0.96 | DYRK1A (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| SCHEMBL25213710 | 0.96 | DYRK1A (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| Hydrochloric Acid SCHEMBL30438968 | 0.95 | DYRK1A (0.37) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| Trifluoroacetic Acid SCHEMBL30438765 | 0.94 | AKR1C3 (0.37) | DYRK1AGSK3BAKR1C3CHEK1ELOVL6 | |
| Sulfuric Acid SCHEMBL30439116 | 0.92 | AKR1C3 (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| Trifluoroacetic Acid SCHEMBL30439111 | 0.90 | AKR1C3 (0.37) | DYRK1AGSK3BAKR1C3ELOVL6 | |
| SCHEMBL25245022 | 0.85 | DYRK1A (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 | |
| SCHEMBL25250558 | 0.84 | AKR1C3 (0.38) | DYRK1AGSK3BAKR1C3ABL1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122167-A1 | Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-17 | — | — | US | claimed |
| EP-4436960-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-10-02 | — | — | EP | claimed |
| WO-2023094305-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | WO | claimed |
| US-20250122167-A1 | Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| EP-4436960-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023094305-A1 | PYRAZINE COMPOUNDS USEFUL IN THE TREATMENT OF PARASITIC PROTOZOAL INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122167-A1 | Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection | CYP3A5, CYP3A43, CYP51A1 | DYRK1A 3328/4885GSK3B 3329/4885AKR1C3 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.